-
-
公开(公告)号：KR100732886B1
公开(公告)日：2007-06-27
申请号：KR1020050106005
申请日：2005-11-07
Applicant: 한국화학연구원
IPC: A61K31/7048 , A61K36/65 , A61P9/12
Abstract: 본 발명은 목단피(Moutan Cortex Radicis) 추출물, 옥시패오니플로린(oxypaeoniflorin), 패오니플로린(paeoniflorin), 메틸패오니플로린(methylpaeoniflorin) 또는 패오니다닌(paeonidanin)을 유효성분으로 함유하는 혈압강하용 조성물에 관한 것이다. 본 발명에 따른 조성물은 혈관 평활근 이완작용을 통해 우수한 혈압강하효과를 나타내므로 고혈압 및 고혈압의 합병증으로 인한 각종 심혈관계질환의 예방 및 치료를 위한 약학 조성물뿐만 아니라 식품첨가물로도 유용하게 사용될 수 있다.
-
Patent Agency Ranking
公开(公告)号：KR1020070050998A
公开(公告)日：2007-05-17
申请号：KR1020050106005
申请日：2005-11-07
Applicant: 한국화학연구원
IPC: A61K31/7048 , A61K36/65 , A61P9/12
CPC classification number: A61K31/7048 , A23L2/52 , A23L29/035 , A23V2200/326 , A23V2200/3262 , A61K36/65 , A61K2236/55 , Y10S514/824 , Y10S514/912
Abstract: 본 발명은 목단피(Moutan Cortex Radicis) 추출물, 옥시패오니플로린(oxypaeoniflorin), 패오니플로린(paeoniflorin), 메틸패오니플로린(methylpaeoniflorin) 또는 패오니다닌(paeonidanin)을 유효성분으로 함유하는 혈압강하용 조성물에 관한 것이다. 본 발명에 따른 조성물은 혈관 평활근 이완작용을 통해 우수한 혈압강하효과를 나타내므로 고혈압 및 고혈압의 합병증으로 인한 각종 심혈관계질환의 예방 및 치료를 위한 약학 조성물뿐만 아니라 식품첨가물로도 유용하게 사용될 수 있다.
Abstract translation: 本发明mokdanpi（牡丹皮皮质Radicis）提取物，氧基大号污泥林（oxypaeoniflorin），L污泥林（芍药苷），甲基1-污泥林（methylpaeoniflorin）或L污泥行进（paeonidanin），用于降低血压，其包含作为活性成分的组合物 Lt。 根据本发明的组合物可以表现出优异的血压通过血管平滑肌松弛作用降低效果使用以及药物组合物，用于预防和治疗由于高血压和高血压并发症各种心血管疾病是作为食品添加剂也是有用的。
-
公开(公告)号：KR100668046B1
公开(公告)日：2007-01-16
申请号：KR1020060023991
申请日：2006-03-15
Applicant: 한국화학연구원
CPC classification number: C08G63/664 , C08G63/66 , A61K47/50 , A61L27/52 , C08G61/12 , C08G2230/00 , C08G2261/126 , C08J9/22
Abstract: Provided is a biocompatible and temperature-sensitive polyethylene glycol/polyester block copolymer, which shows a phase transition depending on variations in temperature to form a gel with a desired shape in vivo, and is useful as a scaffold for tissue engineering. The biocompatible and temperature-sensitive polyethylene glycol/polyester block copolymer comprises: a hydrophilic segment comprising polyethylene glycol; and a biodegradable polyester-based hydrophobic segment comprising a caprolactone segment, paradioxanone segment, trimethylene carbonate segment or a combination thereof. The polyethylene glycol/polyester block copolymer has a molecular weight of 2,000-7,000 g/mole.
Abstract translation: 提供了一种生物相容性和温度敏感性的聚乙二醇/聚酯嵌段共聚物，其显示出依赖于温度变化的相变，以形成具有期望的体内形状的凝胶，并且可用作组织工程的支架。 生物相容性和温度敏感性聚乙二醇/聚酯嵌段共聚物包括：包含聚乙二醇的亲水链段; 以及包含己内酯片段，对二恶烷酮片段，三亚甲基碳酸酯片段或其组合的可生物降解的聚酯基疏水片段。 聚乙二醇/聚酯嵌段共聚物的分子量为2,000-7,000g / mol。
-
公开(公告)号：KR100832552B1
公开(公告)日：2008-05-26
申请号：KR1020060125541
申请日：2006-12-11
Applicant: 한국화학연구원
IPC: A61K9/08 , A61K31/765
CPC classification number: A61K47/34 , A61K9/0019 , A61K9/06 , A61K38/28 , A61K38/38
Abstract: An injection formulation of a drug is provided to release a desired amount of the drug gradually for a desired time to a portion desired by a drug person administered to the drug by using a bio-compatible and thermosensitive polyethyleneglycol/polyester block copolymer to make the drug semi-solid or gel. An injection formulation comprises a hydrophilic portion consisting of polyethyleneglycol having a molecular weight of 350-2,000g/mole and a biodegradable polyester hydrophobic portion containing a caprolactone(CL) segment as an essential ingredient and at least one of a paradioxanone(PDO) segment and a trimethylene carbonate(TMC) segment and is characterized in that it is prepared by mixing a protein or peptide-based drug with a bio-compatible and thermosensitive polyethyleneglycol/biodegradable polyester block copolymer having a molecular weight of 2,000-7,000g/mole, wherein the protein or peptide-based drug is albumin, calcitonin, octreotide, leuprolide, adenosine deaminase, L-asparaginase, urokinase, interferon alpha-2b, interferon beta-1b, human insulin, insulin-like growth factor-1(IGF-1), erythropoietin(EPO), granulocyte colony stimulating factor(G-CSF), human growth hormone(hGH), nerve growth factor(NGF), brain-derived neurotrophic factor(BDNF), neurotrophin-3(NT-3), fibroblast growth factor(FGF), epidermal growth factor(EGF), endothelial growth factor(VEGF), transforming growth factor-beta(TGF-beta) or platelet-derived growth factor(PDGF).
Abstract translation: 提供药物的注射制剂，通过使用生物相容性和热敏性聚乙二醇/聚酯嵌段共聚物将所需量的药物逐渐释放到药物给药的人所需的部分，以制备药物 半固体或凝胶。 注射制剂包含由分子量为350-2,000g / mol的聚乙二醇组成的亲水部分和含有己内酯（CL）链段作为必需成分的可生物降解的聚酯疏水部分和至少一种对二恶烷酮（PDO）链段和 一种三亚甲基碳酸酯（TMC）片段，其特征在于其通过将蛋白质或肽基药物与分子量为2,000-7,000g / mol的生物相容性和热敏聚乙二醇/可生物降解的聚酯嵌段共聚物混合而制备，其中 蛋白质或肽类药物是白蛋白，降钙素，奥曲肽，亮丙瑞林，腺苷脱氨酶，L-天冬酰胺酶，尿激酶，干扰素α-2b，干扰素β-1b，人胰岛素，胰岛素样生长因子-1（IGF-1） ，红细胞生成素（EPO），粒细胞集落刺激因子（G-CSF），人生长激素（hGH），神经生长因子（NGF），脑源性神经营养因子（BDNF），神经营养因子-3（NT-3），成纤维细胞 生长因子（FGF），表皮生长因子（EGF），内皮生长因子（VEGF），转化生长因子-β（TGF-β）或血小板衍生生长因子（PDGF）。
-
公开(公告)号：KR1020070066104A
公开(公告)日：2007-06-27
申请号：KR1020050126879
申请日：2005-12-21
Applicant: 한국화학연구원
IPC: A61K36/708 , A61K31/05 , A61P9/12
CPC classification number: A61K31/065 , A23L2/52 , A23L29/035 , A23V2200/326 , A23V2200/3262 , A61K31/122 , A61K31/343 , A61K36/708 , Y10S514/912
Abstract: 본 발명은 대황(Rhei Rhizoma) 추출물, 피세아타놀(piceatannol), 입실론비니페린(ε-viniferin), 피시온(physcion) 또는 에모딘(emodin)을 유효성분으로 함유하는 혈압 강하용 조성물에 관한 것으로서, 본 발명에 따른 조성물은 혈관 평활근 이완작용을 통해 우수한 혈압 강하효과를 나타내므로, 고혈압 및 고혈압의 합병증으로 인한 각종 심혈관계 질환의 예방 및 치료를 위한 약학 조성물 뿐만 아니라 식품 조성물로도 유용하게 사용될 수 있다.
-
公开(公告)号：KR100732888B1
公开(公告)日：2007-06-27
申请号：KR1020050126879
申请日：2005-12-21
Applicant: 한국화학연구원
IPC: A61K36/708 , A61K31/05 , A61P9/12
Abstract: An anti-hypertensive composition comprising the extract of Rhei rhizoma or active compounds isolated therefrom is provided to induce smooth muscle relaxation of the blood vessel, so that the composition is useful for treatment of hypersensitive and hypersensitive complications. The anti-hypertensive composition comprises the extract of Rhei rhizoma or active compounds isolated therefrom including piceatannol represented by the formula(1), epsilon-viniferin represented by the formula(2), physcion represented by the formula(3) or emodin represented by the formula(4) as an effective ingredient. The Rhei rhizoma extract is prepared with an organic solvent of methanol, ethanol, butanol, dichloromethane or ethylacetate; and the active compounds are isolated from the Rhei rhizoma extract by subjecting the Rhei rhizoma extract to reverse phase or silica gel column chromatography.
Abstract translation: 提供包含大黄提取物或从其中分离的活性化合物的抗高血压组合物，以诱导血管的平滑肌松弛，使得该组合物可用于治疗过敏和过敏性并发症。 该抗高血压组合物含有大黄提取物或由其分离的活性化合物，包括由式（1）表示的白皮素醇，由式（2）表示的ε-v草素，由式（3）表示的化合物或由 公式（4）作为有效成分。 大黄提取物用甲醇，乙醇，丁醇，二氯甲烷或乙酸乙酯等有机溶剂制备; 通过将大黄根茎提取物进行反相或硅胶柱色谱从大黄根提取物中分离活性化合物。
-
-
-
-
-
-
Search Results
7
records
(took 0.028 seconds)
